Clarity-IA^®

A next-generation anesthesia system expanding the use of inhaled anesthetics worldwide.

Clarity-IA^® is based on a worldwide exclusively licensed portfolio of 30 patents and applications.

Unique platform technology:

Converts any existing ventilator into the equivalent of a $75,000 anesthesia machine WITH ZERO CAPITAL COSTS to the hospital.
Self-regulation technology adapts in real time to changing conditions, ensuring accuracy of dosing and reducing staff work load.
Disposable component allows the device to isolate airflow between each patient and the ventilator, thereby increasing patient safety by eliminating the risk of inhaling cross-contaminated air.
Platform technology lends itself to deliver an array of inhaled drugs.
Initial Indication: Intended for the delivery and maintenance of inhaled medical gases for patients weighing between 80-330 lbs and requiring inhalation anesthesia and sedation during mechanical ventilation under the care of a trained healthcare professional.

Clarity-IA surgical suction system on wheeled cart

Clarity-IA^® addresses the widely recognized link between sedation practices and incidence of delirium in patients requiring life support (i.e. breathing on a ventilator).

Delirium Focus

Delirium is common with approximately 75% of patients on mechanical ventilation (or life support),* resulting in an estimated $140 billion per year in post-hospital care.**

The Rheos Clarity-IA^® next-gen system breaks this cycle by improving the precision of sedation and anesthesia.

Inhaled sedatives and anesthetics clear faster, reducing tolerance buildup in comparison to IV sedation.

Additional benefits include:



Lowering IV sedation dosing and duration outside approved labels



Reducing risk of delirium and pneumonia



Minimizing the cost and time spent in the ICU

Sources:

* Girard, et. al., (2018). Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study. The Lancet, 6(3), 213-222. https://doi.org/10.1016/S2213-2600(18)30062-6

** Leslie, DL & Inouye, SK, (2011). The importance of delirium: economic and societal costs. Journal of the American Geriatric Society, 59(S2), S241-3. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2011.03671.x

Clinical Overview

Program	Regulatory Pathway	Stage	Industry Partner
Clarity Gas Delivery System Inhalational anesthesia	510K	In Process	Agreement Signed
Clarity-IA® Next-Gen ICU sedation	PMA/505(b)(2)	Pre-Clinical	Identified
Clarity-XDS (Xenon)	License	In Development	Identified

Clarity-IA^®

A next-generation anesthesia system expanding the use of inhaled anesthetics worldwide.

Clarity-IA^® is based on a worldwide exclusively licensed portfolio of 30 patents and applications.

Unique platform technology:

Converts any existing ventilator into the equivalent of a $75,000 anesthesia machine WITH ZERO CAPITAL COSTS to the hospital.

Self-regulation technology adapts in real time to changing conditions, ensuring accuracy of dosing and reducing staff work load.

Disposable component allows the device to isolate airflow between each patient and the ventilator, thereby increasing patient safety by eliminating the risk of inhaling cross-contaminated air.

Platform technology lends itself to deliver an array of inhaled drugs.

Initial Indication: Intended for the delivery and maintenance of inhaled medical gases for patients weighing between 80-330 lbs and requiring inhalation anesthesia and sedation during mechanical ventilation under the care of a trained healthcare professional.

Clarity-IA^® addresses the widely recognized link between sedation practices and incidence of delirium in patients requiring life support (i.e. breathing on a ventilator).

Delirium Focus

Delirium is common with approximately 75% of patients on mechanical ventilation (or life support),* resulting in an estimated $140 billion per year in post-hospital care.**

The Rheos Clarity-IA^® next-gen system breaks this cycle by improving the precision of sedation and anesthesia.

Inhaled sedatives and anesthetics clear faster, reducing tolerance buildup in comparison to IV sedation.

Additional benefits include:

Lowering IV sedation dosing and duration outside approved labels

Reducing risk of delirium and pneumonia

Minimizing the cost and time spent in the ICU

Sources:

* Girard, et. al., (2018). Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study. The Lancet, 6(3), 213-222. https://doi.org/10.1016/S2213-2600(18)30062-6

** Leslie, DL & Inouye, SK, (2011). The importance of delirium: economic and societal costs. Journal of the American Geriatric Society, 59(S2), S241-3. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2011.03671.x

Clinical Overview

Program

Regulatory Pathway

Stage

Industry Partner

Clarity Gas Delivery System
Inhalational anesthesia

510K

In Process

Agreement Signed

Clarity-IA®
Next-Gen ICU sedation

PMA/505(b)(2)

Pre-Clinical

Identified

Clarity-XDS
(Xenon)

License

In Development

Identified

Clarity-IA®

A next-generation anesthesia system expanding the use of inhaled anesthetics worldwide.

Clarity-IA® is based on a worldwide exclusively licensed portfolio of 30 patents and applications.

Unique platform technology:

Converts any existing ventilator into the equivalent of a $75,000 anesthesia machine WITH ZERO CAPITAL COSTS to the hospital.

Self-regulation technology adapts in real time to changing conditions, ensuring accuracy of dosing and reducing staff work load.

Disposable component allows the device to isolate airflow between each patient and the ventilator, thereby increasing patient safety by eliminating the risk of inhaling cross-contaminated air.

Platform technology lends itself to deliver an array of inhaled drugs.

Initial Indication: Intended for the delivery and maintenance of inhaled medical gases for patients weighing between 80-330 lbs and requiring inhalation anesthesia and sedation during mechanical ventilation under the care of a trained healthcare professional.

Clarity-IA® addresses the widely recognized link between sedation practices and incidence of delirium in patients requiring life support (i.e. breathing on a ventilator).

Delirium Focus

Delirium is common with approximately 75% of patients on mechanical ventilation (or life support),* resulting in an estimated $140 billion per year in post-hospital care.**

The Rheos Clarity-IA® next-gen system breaks this cycle by improving the precision of sedation and anesthesia.

Inhaled sedatives and anesthetics clear faster, reducing tolerance buildup in comparison to IV sedation.

Additional benefits include:

Lowering IV sedation dosing and duration outside approved labels

Reducing risk of delirium and pneumonia

Minimizing the cost and time spent in the ICU

Sources:

* Girard, et. al., (2018). Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study. The Lancet, 6(3), 213-222. https://doi.org/10.1016/S2213-2600(18)30062-6

** Leslie, DL & Inouye, SK, (2011). The importance of delirium: economic and societal costs. Journal of the American Geriatric Society, 59(S2), S241-3. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2011.03671.x

Clinical Overview

Program

Regulatory Pathway

Stage

Industry Partner

Clarity Gas Delivery System Inhalational anesthesia

510K

In Process

Agreement Signed

Clarity-IA® Next-Gen ICU sedation

PMA/505(b)(2)

Pre-Clinical

Identified

Clarity-XDS (Xenon)

License

In Development

Identified

Clarity-IA^®

Clarity-IA^® is based on a worldwide exclusively licensed portfolio of 30 patents and applications.

Clarity-IA^® addresses the widely recognized link between sedation practices and incidence of delirium in patients requiring life support (i.e. breathing on a ventilator).

The Rheos Clarity-IA^® next-gen system breaks this cycle by improving the precision of sedation and anesthesia.

Clarity Gas Delivery System
Inhalational anesthesia

Clarity-IA®
Next-Gen ICU sedation

Clarity-XDS
(Xenon)